Elobixibat Hydrate is a potent, selective inhibitor of the ileal bile acid transporter (IBAT), a novel small molecule drug currently in development for the treatment of chronic constipation and irritable… Read more
Elobixibat Hydrate is a potent, selective inhibitor of the ileal bile acid transporter (IBAT), a novel small molecule drug currently in development for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C). This category features a comprehensive range of Elobixibat Hydrate reference standards, including the active pharmaceutical ingredient (API), related pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these high-quality materials for critical tasks such as impurity profiling, the validation of analytical methods, and routine quality control throughout the drug's clinical evaluation. By providing accurate benchmarks for identification and quantification, these compounds ensure precision in stability testing and metabolic studies. Researchers and analysts rely on these standards to maintain rigorous compliance and support the integrity of analytical data during all phases of drug development and regulatory submission.